

AWARD NUMBER: W81XWH-16-1-0717

TITLE: Identification of Causes and Treatments for Chronic Pain in a Model of Gulf War Illness

PRINCIPAL INVESTIGATOR: Peter Grace

**RECIPIENT: University of Texas M D Anderson Cancer Center
Houston, TX 77030**

REPORT DATE: October 2017

TYPE OF REPORT: Annual

**PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012**

DISTRIBUTION STATEMENT:

Approved for Public Release; Distribution is unlimited.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2017		2. REPORT TYPE Annual		3. DATES COVERED 30 Sep 2016 - 29 Sep 2017	
4. TITLE AND SUBTITLE Identification of Causes and Treatments for Chronic Pain in a Model of Gulf War Illness				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-16-1-0717	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Peter Grace PGrace@mdanderson.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Texas M D Anderson Cancer Center Houston, TX 77030				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Over the past 3 decades, 25-30% of veterans from the 1990-1991 Gulf War have consistently reported numerous unexplained chronic health symptoms affecting their quality of life, which has been termed Gulf War Illness (GWI). Musculoskeletal pain is a principal symptom of GWI, and affects up to 17% of veterans with GWI. Pain is not only a major quality of life burden for the patient, but exacts a substantial economic toll in terms of direct health care costs and absenteeism. Epidemiological studies have identified exposure to acetylcholinesterase inhibitors as a potential cause of GWI, as well as the stress of war as a sensitizing condition that might predispose soldiers to GWI. Rodent models have recapitulated the symptoms of GWI with exposure to these agents. With only one exception, pain has not been assessed in animal studies, despite being a principal symptom of GWI. Several mechanisms underlying GWI symptoms have been posited from animal studies, including neuroinflammatory signaling. However, no neuroimmune pharmacotherapies have been assessed in any model of GWI.					
15. SUBJECT TERMS- None listed					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 16	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

Page No.

1. Introduction.....	4
2. Keywords.....	4
3. Accomplishments.....	4
4. Impact.....	9
5. Changes/Problems.....	10
6. Products.....	12
7. Participants & Other Collaborating Organizations.....	14
8. Special Reporting Requirements.....	N/A
9. Appendices.....	N/A

1. **INTRODUCTION:** Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.

Musculoskeletal pain is a principal symptom of Gulf War Illness (GWI), and affects up to 17% of Gulf War veterans. This project uses a rat model to investigate the neurobiological basis of pain in GWI and to test putative neuroimmune pharmacotherapies. Aim 1 determines whether a model of GWI sensitizes rats to a subsequent subthreshold nociceptive stimulus, resulting in induction of sustained pain-relevant behaviors. Aim 2 assesses neuroinflammatory markers in the pain neuraxis during the initiation and maintenance phase of musculoskeletal pain. Aim 3 uses pharmacological inhibitors against neuroinflammatory pathways to determine whether they reverse musculoskeletal pain in GWI.

2. **KEYWORDS:** Provide a brief list of keywords (limit to 20 words).

Musculoskeletal pain, Gulf War Illness, neuroinflammation, TLR4, microglia, S1PR1, p38

3. **ACCOMPLISHMENTS:** The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants Officer whenever there are significant changes in the project or its direction.

What were the major goals of the project?

List the major goals of the project as stated in the approved SOW. If the application listed milestones/target dates for important activities or phases of the project, identify these dates and show actual completion dates or the percentage of completion.

Major Task 1: (Preliminary activities) Obtain approval from the University of Texas MD Anderson Cancer Center Institutional Animal Care & Use Committee (IACUC) and ACURO for all animal work in the proposal

Milestone 1: animal protocol is approved by MD Anderson IACUC and ACURO.

Major Task 2: Acidic/normal saline administered 14 days after final DFP injection for behavior.

Corticosterone (CORT)/vehicle administration followed by diisopropylfluorophosphate (DFP)/vehicle; intramuscular acidic vs. normal saline delivered. Behavioral testing (von Frey, Hargreaves, conflict avoidance) every 3-7 days until all rats return to baseline thresholds.

Major Task 3: Acidic/normal saline administered 180 days after final DFP injection for behavior.

CORT/vehicle administration followed by DFP/vehicle; intramuscular acidic vs. normal saline delivered. Behavioral testing (von Frey, Hargreaves, conflict avoidance) every 3-7 days until all rats return to baseline thresholds (months 2-11).

Milestone 2: the behavioral effect of GWI on sensitization to musculoskeletal pain is defined.

Major Task 4: Acidic/normal saline administered 14 days after final DFP injection for tissue analyses.

CORT/vehicle administration followed by DFP/vehicle; intramuscular acidic vs. normal saline delivered. Euthanasia and necropsy at days 5 and 20 post acidic/normal saline, and tissue analysis performed (ELISA, Western Blot, LC-MS).

Major Task 5: Acidic/normal saline administered 180 days after final DFP injection for tissue analyses.

CORT/vehicle administration followed by DFP/vehicle; intramuscular acidic vs. normal saline delivered. Euthanasia and necropsy at days 5 and 20 post acidic/normal saline, and tissue analysis performed (ELISA, Western Blot, LC-MS).

Milestone 3: the association between GWI-induced musculoskeletal pain and neuroinflammation, as well as the optimal timepoint for immuno-modulator administration in Aim 3 is defined.

Major Task 6: Acidic/normal saline administered 14 days after final DFP injection; pharmacological reversal.

CORT followed by DFP; intramuscular acidic saline delivered. Seven-day administration of FTY720, (+)-Naltrexone, losmapimod, or minocycline. Behavioral testing (von Frey, Hargreaves, conflict avoidance) every 3-7 days until all rats return to baseline thresholds. Serum samples analysed by ELISA.

Major Task 7: Acidic/normal saline administered 180 days after final DFP injection; pharmacological reversal.

CORT followed by DFP; intramuscular acidic saline delivered. Seven-day administration of FTY720, (+)-Naltrexone, losmapimod, or minocycline. Behavioral testing (von Frey, Hargreaves, conflict avoidance) every 3-7 days until all rats return to baseline thresholds. Serum samples analysed by ELISA.

Milestone 4: Pharmacological attenuation of GWI-induced musculoskeletal pain is defined

Milestone 5: Final report is completed; publication of 1-2 peer reviewed papers

What was accomplished under these goals?

For this reporting period describe: 1) major activities; 2) specific objectives; 3) significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative); and/or 4) other achievements. Include a discussion of stated goals not met. Description shall include pertinent data and graphs in sufficient detail to explain any significant results achieved. A succinct description of the methodology used shall be provided. As the project progresses to completion, the emphasis in reporting in this section should shift from reporting activities to reporting accomplishments.

Major Task 1: Completed.

IACUC and ACURO approval was obtained

Major Task 2, Acidic/normal saline administered 14 days after final DFP injection for behavior: In progress

The aim of this task is to determine whether a model of GWI (CORT+DFP) sensitizes rats to a subsequent subthreshold nociceptive stimulus (a single intramuscular (IM) acidic saline administration), resulting in induction of sustained nociceptive behaviors. As shown in **Figure 1**, we report that acidic saline dramatically induces ipsilateral hindpaw allodynia in the GWI model (CORT/DFP). Neither CORT/DFP or acidic saline alone substantially reduce withdrawal thresholds. The potentiation of hindpaw allodynia by acidic saline was limb-specific; the withdrawal threshold of the contralateral paw, seen in **Figure 2**, was not influenced by the IM acidic saline injection. We further confirmed the efficacy of the initial CORT drinking water treatment by measuring daily body weights from days 2-7 during CORT/vehicle exposure. As seen in **Figure 3**, while body weights did not differ between groups at baseline, CORT treatment resulted in a significant decrease in body weight over time, demonstrating a physiological outcome of prolonged CORT exposure.

We have also optimized a protocol for the Coy conflict avoidance system. As shown in **Figure 4**, rats with pain (CCI) increase the latency to enter the hallway.




Figure 1. Baseline nociceptive measures were performed, and rats received either CORT or vehicle control in the drinking water for 7 days. On day 7, rats received a single suncutaneous injection of DFP or vehicle. Rats were allowed to recover from the acute DFP toxicity for 1 week and, after pre-injection behavioral testing, received a single, unilateral IM injection of acidic saline (pH 4) or normal saline (pH 7) into the gastrocnemius muscle. Von Frey testing of the ipsilateral paw followed on days 5, 10, 15, and 20 after acidic/normal saline injection.




Figure 2. Withdrawal threshold to von Frey filaments of the hindpaw contralateral to the IM injection of acidic or normal saline. In contrast to the ipsilateral paw (Figure 1), the withdrawal threshold was not influenced by the IM acidic saline injection.




Figure 3. Daily body weights during CORT/vehicle treatment. Starting on day 0, homecage water was replaced with bottles containing either CORT (400 μ g/mL in 1.5% ethanol) or vehicle (1.5% ethanol) and treatment lasted 7 days. Body weights were recorded at day 0 and days 2-7 during treatment.




Figure 4. Following three days of habituation in which rats explore the runway, nociceptive probes are raised (4 mm above compartment floor) during a test session, and the latency to enter the hallway is recorded.

Major Task 4, Acidic/normal saline administered 14 days after final DFP injection for tissue analyses: In progress

The aim of this task is to analyze multiple tissues for a range of neuroinflammatory markers for activation and signaling by immune cells and glia.

Rats received either CORT or vehicle control in the drinking water for 7 days. On day 7, rats received a single subcutaneous (SC) injection of DFP or vehicle. Rats were allowed to recover from the acute DFP toxicity, and received a single, bilateral IM injection of acidic saline (pH 4) or normal saline (pH 7) into the gastrocnemius muscles 1 week later. Rats were euthanized at either 5 or 20 days after the IM acidic/normal saline injection, and the following tissues were collected: serum, gastrocnemius muscle, dorsal root ganglia, lumbar spinal cords. Tissues are currently frozen at -80 °C while awaiting analysis.

What opportunities for training and professional development has the project provided?

If the project was not intended to provide training and professional development opportunities or there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe opportunities for training and professional development provided to anyone who worked on the project or anyone who was involved in the activities supported by the project. “Training” activities are those in which individuals with advanced professional skills and experience assist others in attaining greater proficiency. Training activities may include, for example, courses or one-on-one work with a mentor. “Professional development” activities result in increased knowledge or skill in one’s area of expertise and may include workshops, conferences, seminars, study groups, and individual study. Include participation in conferences, workshops, and seminars not listed under major activities.

The research personnel listed on this project have had extensive training and professional development opportunities. These include the technical aspects of this project, like the von Frey test, Hargreaves test, Mechanical Conflict-Avoidance System, necropsy, and Western blotting.

Professional development opportunities include poster presentations at conferences, and oral presentations at lab meetings.

How were the results disseminated to communities of interest?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how the results were disseminated to communities of interest. Include any outreach activities that were undertaken to reach members of communities who are not usually aware of these project activities, for the purpose of enhancing public understanding and increasing interest in learning and careers in science, technology, and the humanities.

This project and the latest results were presented at a Gulf War Veterans Illness Meeting, held at the Palo Alto VA in September 2017. The presentation, given by the PI, was entitled “Neuroimmune mechanisms of chronic pain: implications for Gulf War illness”.

The slides were made publically available through Twitter and Facebook to the network of Veterans maintained through the Icahn School of Medicine at Mount Sinai. The live talk was also available to this Veterans network through videoconference.

What do you plan to do during the next reporting period to accomplish the goals?

Describe briefly what you plan to do during the next reporting period to accomplish the goals and objectives.

Major Tasks 2-5 will be completed within the next reporting period.

- 4. IMPACT:** Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:

What was the impact on the development of the principal discipline(s) of the project?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how findings, results, techniques that were developed or extended, or other products from the project made an impact or are likely to make an impact on the base of knowledge, theory, and research in the principal disciplinary field(s) of the project. Summarize using language that an intelligent lay audience can understand (Scientific American style).

Nothing to report.

What was the impact on other disciplines?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how the findings, results, or techniques that were developed or improved, or other products from the project made an impact or are likely to make an impact on other disciplines.

Nothing to report.

What was the impact on technology transfer?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe ways in which the project made an impact, or is likely to make an impact, on commercial technology or public use, including:

- *transfer of results to entities in government or industry;*
- *instances where the research has led to the initiation of a start-up company; or*
- *adoption of new practices.*

Nothing to report.

What was the impact on society beyond science and technology?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how results from the project made an impact, or are likely to make an impact, beyond the bounds of science, engineering, and the academic world on areas such as:

- *improving public knowledge, attitudes, skills, and abilities;*
- *changing behavior, practices, decision making, policies (including regulatory policies), or social actions; or*
- *improving social, economic, civic, or environmental conditions.*

Nothing to report.

- 5. CHANGES/PROBLEMS:** The Project Director/Principal Investigator (PD/PI) is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants Officer whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, “Nothing to Report,” if applicable:

Changes in approach and reasons for change

Describe any changes in approach during the reporting period and reasons for these changes.

Remember that significant changes in objectives and scope require prior approval of the agency.

Nothing to report.

Actual or anticipated problems or delays and actions or plans to resolve them

Describe problems or delays encountered during the reporting period and actions or plans to resolve them.

It was initially projected that Major Tasks 2 and 3 would be complete by the end of Year 1. When this projection was made, it was not foreseen that the PI would move to another

Institution, set up a new lab, and hire skilled staff to carry out this project. In addition, unforeseen personnel turnover occurred when a technician left, and the position had to be backfilled. Because this move and personnel turnover occurred, there have been significant disruptions to our productivity, and the initial projections were only partially met.

However, these delays in setting up a new lab still benefit the project. Personnel with skills in neuroimmunology and neuroscience were hired and trained in many of the procedures relevant to this project (Tim Fabisiak, Nov 2016-Jun 2017; Michael Lacagnina, Jan 2017; Sabina Lorca, Sep 2017).

The lab was outfitted with new equipment to support this project, including minor equipment, like pipettes (variable volume, multichannel, repeater, serological), Hamilton microinjectors, glassware, warming ovens, water baths, centrifuges, fume hoods, heating blocks and plates, shakers and rotators, analytical scales, power supplies and tanks for running gels, iBlot membrane transfer, and a dissection microscope. We have also purchased major equipment to facilitate this study, including a BioTek Synergy HTX Multi-Mode plate reader for absorbance, fluorescent, and bioluminescent assays, GE ImageQuant LAS 4000 mini for sensitive and robust digital chemiluminescence imaging of protein and DNA samples in gels and membranes, Millipore Biopak water polisher, -80 °C freezer, 2 x -20 °C freezers, and 4 °C refrigerator.

We have outfitted a surgery room with an anesthesia system, perfusion pumps, surgical instruments, and a fume hood for paraformaldehyde perfusions. Behavioral apparatus have also been purchased and installed, including testing platforms, von Frey filaments, IITC apparatus plantar test for thermal hyperalgesia, and a Noldus Coy conflict avoidance system.

In addition, we were impacted by Hurricane Harvey. The University of Texas MD Anderson Cancer Center was closed from August 26th through September 4th for a total of 10 days due to the extreme circumstances of Hurricane Harvey. During this time, the institution was inaccessible as a result of severe flooding throughout the Texas Medical Center, city of Houston, and the Greater Houston Metro area which made it impossible for faculty and staff to arrive to work safely. This closure delayed commencement of experiments, and analysis of tissues. Additionally, Hurricane Harvey continues to severely impact approximately one third of our employees who are addressing personal issues related to family, health, home, auto and insurance matters. This includes Dr. Lacagnina, who is performing the studies under this grant. We do not foresee a return to normal operations for at least the next three months.

Establishing these facilities and training personnel has now restored our capacity to complete the project successfully. A major weather event is not anticipated over the remainder of the performance period, and we therefore anticipate no further major delays in productivity.

Changes that had a significant impact on expenditures

Describe changes during the reporting period that may have had a significant impact on expenditures, for example, delays in hiring staff or favorable developments that enable meeting objectives at less cost than anticipated.

Nothing to report.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Describe significant deviations, unexpected outcomes, or changes in approved protocols for the use or care of human subjects, vertebrate animals, biohazards, and/or select agents during the reporting period. If required, were these changes approved by the applicable institution committee (or equivalent) and reported to the agency? Also specify the applicable Institutional Review Board/Institutional Animal Care and Use Committee approval dates.

Significant changes in use or care of human subjects

N/A

Significant changes in use or care of vertebrate animals.

Nothing to report.

Significant changes in use of biohazards and/or select agents

Nothing to report.

6. PRODUCTS: List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state “Nothing to Report.”

- **Publications, conference papers, and presentations**

Report only the major publication(s) resulting from the work under this award.

Journal publications. *List peer-reviewed articles or papers appearing in scientific, technical, or professional journals. Identify for each publication: Author(s); title; journal; volume; year; page numbers; status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

Lacagnina MJ, Watkins LR, and Grace PM. Toll-like receptors and their role in persistent pain. Pharmacol Ther. 2017. (Epub Oct 04)

Books or other non-periodical, one-time publications. *Report any book, monograph, dissertation, abstract, or the like published as or in a separate publication, rather than a periodical or series. Include any significant publication in the proceedings of a one-time conference or in the report of a one-time study, commission, or the like. Identify for each one-time publication: Author(s); title; editor; title of collection, if applicable; bibliographic information; year; type of publication (e.g., book, thesis or dissertation); status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

Nothing to report.

Other publications, conference papers, and presentations. *Identify any other publications, conference papers and/or presentations not reported above. Specify the status of the publication as noted above. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (*) if presentation produced a manuscript.*

Lacagnina MJ, Fabisiak TJ, Sullivan K, O'Callaghan J, Watkins LR, Grace PM (2017). A neuroimmune basis for chronic pain in a rat model of gulf war illness. Society for Neuroscience, 2017: Washington DC.

- **Website(s) or other Internet site(s)**

List the URL for any Internet site(s) that disseminates the results of the research activities. A short description of each site should be provided. It is not necessary to include the publications already specified above in this section.

Nothing to report.

- **Technologies or techniques**

Identify technologies or techniques that resulted from the research activities. In addition to a description of the technologies or techniques, describe how they will be shared.

Nothing to report.

- **Inventions, patent applications, and/or licenses**

Identify inventions, patent applications with date, and/or licenses that have resulted from the research. State whether an application is provisional or non-provisional and indicate the application number. Submission of this information as part of an interim research performance progress report is not a substitute for any other invention reporting required under the terms and conditions of an award.

Nothing to report.

- **Other Products**

Identify any other reportable outcomes that were developed under this project. Reportable outcomes are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment, and/or rehabilitation of a disease, injury or condition, or to improve the quality of life. Examples include:

- *data or databases;*
- *biospecimen collections;*
- *audio or video products;*
- *software;*
- *models;*
- *educational aids or curricula;*
- *instruments or equipment;*
- *research material (e.g., Germplasm; cell lines, DNA probes, animal models);*

- *clinical interventions;*
- *new business creation; and*
- *other.*

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate “no change.”

<i>Name:</i>	<i>Peter Grace</i>
<i>Project Role:</i>	<i>Principal Investigator</i>
<i>Researcher Identifier (e.g. ORCID ID):</i>	<i>orcid.org/0000-0002-8999-1220</i>
<i>Nearest person month worked:</i>	<i>4</i>
<i>Contribution to Project:</i>	<i>Dr. Grace was responsible for overall project management, oversight of all experimental designs and execution, and presentation of the results at national forums. Dr. Grace also trained personnel on experimental procedures.</i>

<i>Name:</i>	<i>Michael Lacagnina</i>
<i>Project Role:</i>	<i>Postdoctoral Researcher</i>
<i>Researcher Identifier (e.g. ORCID ID):</i>	<i>n/a</i>
<i>Nearest person month worked:</i>	<i>5</i>
<i>Contribution to Project:</i>	<i>Dr. Lacagnina conducted experiments, including drug preparation, injections, behavioral assessments, tissue collection, and performed data analysis. His managerial responsibilities included procuring materials required to complete the project.</i>

<i>Name:</i>	<i>Timothy Fabisiak</i>
<i>Project Role:</i>	<i>Research Assistant II</i>

Researcher Identifier (e.g. ORCID ID): n/a
Nearest person month worked: 3
Contribution to Project: Mr. Fabisiak's responsibilities included drug preparation, injections, and tissue collection. Managerial responsibilities included procuring materials required to complete the project and performing daily animal monitoring.

Name: Sabina Lorca
Project Role: Research Assistant II
Researcher Identifier (e.g. ORCID ID): n/a
Nearest person month worked: 1
Contribution to Project: Ms. Lorca's responsibilities included drug preparation, injections, and tissue collection. Managerial responsibilities included procuring materials required to complete the project and performing daily animal monitoring.

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

If there is nothing significant to report during this reporting period, state "Nothing to Report."

If the active support has changed for the PD/PI(s) or senior/key personnel, then describe what the change has been. Changes may occur, for example, if a previously active grant has closed and/or if a previously pending grant is now active. Annotate this information so it is clear what has changed from the previous submission. Submission of other support information is not necessary for pending changes or for changes in the level of effort for active support reported previously. The awarding agency may require prior written approval if a change in active other support significantly impacts the effort on the project that is the subject of the project report.

Nothing to report.

What other organizations were involved as partners?

If there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe partner organizations – academic institutions, other nonprofits, industrial or commercial firms, state or local governments, schools or school systems, or other organizations (foreign or domestic) – that were involved with the project. Partner organizations may have provided financial or in-kind support, supplied facilities or equipment, collaborated in the research, exchanged personnel, or otherwise contributed.

Provide the following information for each partnership:

Organization Name:

Location of Organization: (if foreign location list country)

Partner's contribution to the project (identify one or more)

- *Financial support;*
- *In-kind support (e.g., partner makes software, computers, equipment, etc.,*

- *available to project staff);*
- *Facilities (e.g., project staff use the partner's facilities for project activities);*
- *Collaboration (e.g., partner's staff work with project staff on the project);*
- *Personnel exchanges (e.g., project staff and/or partner's staff use each other's facilities, work at each other's site); and*
- *Other.*

Nothing to report.

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS: For collaborative awards, independent reports are required from BOTH the Initiating PI and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to <https://ers.amedd.army.mil> for each unique award.

QUAD CHARTS: If applicable, the Quad Chart (available on <https://www.usamraa.army.mil>) should be updated and submitted with attachments.

Nothing to report.

9. **APPENDICES:** Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.

Nothing to report.